Ideaya Biosciences Inc (IDYA)

IDEAYA Biosciences, Inc. is a clinical-stage precision medicine oncology company focused on discovering and developing targeted therapies for patient groups identified through molecular diagnostics. Its lead program, Darovasertib, is an oral protein kinase C inhibitor being studied for uveal melanoma and other cancers associated with GNAQ/11 mutations, including multiple combination and treatment-setting trials with crizotinib. The company’s pipeline also includes several early-stage and preclinical programs, such as IDE849, IDE034, IDE161, IDE705 (GSK101), IDE397, IDE892, IDE574, and IDE275, covering a range of oncology targets and mutation-defined tumors. IDEAYA also supports its research platform through tools such as DECIPHER, INQUIRE, and HARMONY, and has established strategic alliances with companies and research organizations including GlaxoSmithKline, Pfizer, Gilead Sciences, Novartis, Biocytogen, Cancer Research UK, the University of Manchester, Jiangsu Hengrui Pharmaceuticals, and Les Laboratoires Servier. Founded in 2015, the company is headquartered in South San Francisco, California, and its common stock trades on NASDAQ under the symbol IDYA.

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.